MedTrace Logo

Effect of Resveratrol and Vitamin C on Insulin Resistance Among Postmenopausal Women

NCT03090997 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2021-12-28

No results posted yet for this study

Summary

Hormonal and metabolic changes because of postmenopause increase body weight, central abdominal fat, alter lipid profile and insulin resistance, those factors increase the risk up to 60% to develop metabolic syndrome, diabetes and cardiovascular diseases. Because there is no efficient antioxidant therapy in postmenopausal women, this study proposes a therapy with resveratrol and vitamin C to increase the total antioxidant capacity; as well as to decrease insulin resistance and in consequence decreased the risk of diabetes, metabolic syndrome and cardiovascular disease

Conditions

Interventions

DIETARY_SUPPLEMENT

vitamin C (500 mg / day) + placebo

Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)

DIETARY_SUPPLEMENT

resveratrol (500 mg / day) + placebo

Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)

DIETARY_SUPPLEMENT

vitamin C (500 mg / day) and resveratrol (500 mg / day)

Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)

Sponsors & Collaborators

  • Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes

    lead OTHER_GOV

Principal Investigators

  • Araceli Montoya-Estrada, PhD · Instituto Nacional de Perinatología Isidro Espinosa de los Reyes

  • Guillermo F Ortiz-Luna, MD · Instituto Nacional de Perinatología Isidro Espinosa de los Reyes

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-15
Primary Completion
2022-01-30
Completion
2022-02-28

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03090997 on ClinicalTrials.gov